Lung Cancer Therapeutics Market Size, Share, Industry Overview,

• Posted by harry joe Jan 20 Filed in Business #Lung Cancer Therapeutics Market Size  #Lung Cancer Therapeutics Market share  #Lung Cancer Therapeutics Market Trends  56 views
  click to rate

  IMARC Group, a leading market research company, has recently released a report titled "Lung Cancer Therapeutics Market Report by Therapy (Targeted Therapy, Immunotherapy, Radiation Therapy, Chemotherapy), Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Region 2025-2033." The study provides a detailed analysis of the industry, including the lung cancer therapeutics market size, trends, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

  Lung Cancer Therapeutics Market Highlights:

  The global lung cancer therapeutics market size reached USD 33,061.0 Million in 2024 and is expected to reach USD 72,610.7 Million by 2033. Exhibiting a CAGR of 9.14% during the forecast period from 2025 to 2033, the market growth is propelled by the increasing incidence of lung cancer aggravated by smoking and environmental pollution, advances in individualized gene-profile-based treatment, and technological progress in early disease diagnosis.

  Study Assumption Years

  • Base Year: 2024
  • Historical Year/Period: 2019-2024
  • Forecast Year/Period: 2025-2033

  Lung Cancer Therapeutics Market Key Takeaways

  • Current Market Size: USD 33,061.0 Million in 2024
  • CAGR: 9.14% (2025-2033)
  • Forecast Period: 2025-2033
  • The high prevalence and mortality of lung cancer globally fuel substantial demand for lung cancer therapeutics.
  • Personalized medicine is becoming prominent as therapies targeting specific genetic mutations in tumor cells increase.
  • AI and machine learning adoption in diagnostics enhance treatment precision and accessibility.
  • North America leads the market due to robust healthcare infrastructure and expenditure, while Asia Pacific gains from rising healthcare awareness.
  • The high cost of new cancer therapies challenges accessibility in low- and middle-income countries, opening opportunities for cost-effective generics and biosimilars.

  Claim Your Free "Lung Cancer Therapeutics Market" Insights Sample PDF: https://www.imarcgroup.com/lung-cancer-therapeutics-market/requestsample

  Market Growth Factors:

  The major driver of the market is the high prevalence and mortality from lung cancer worldwide. Because lung cancer occurs so often, people demand many treatment drugs now and always since causes such as smoking and pollution increase. The American Cancer Society estimated 234,580 new lung cancer cases and 125,070 lung cancer deaths would occur in 2024 regarding lung cancer in the United States. This stresses the clinical need regarding new therapeutics and diagnostics.

  The market is increased on account of the development of personalized medicine, whereas targeted drugs acting on specific mutations in tumor cells are more efficacious and cause fewer adverse effects than standard chemotherapy. In particular, it seems likely that personalized medicine, based on understanding and assessment of genetic influences and diagnostic advances enabled by artificial intelligence (AI) and machine learning, will be fundamental to lung cancer treatment in the near future.

  Technological advancements continue to change the algorithm of the lung cancer therapeutics market. Developments in imaging technologies for diagnosis, artificial intelligence-based diagnostic testing, improved minimally intrusive surgical procedures, radiation technology, and drug delivery systems such as nanoparticle-based chemotherapy and biopharmaceuticals are some of the factors fueling the growth of the lung cancer therapeutics market. These technologies improve the accuracy of diagnosis and increase the effectiveness of the treatment.

  Market Segmentation:

  The lung cancer therapeutics market segmentation includes:

  Breakup by Therapy:

  • Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
  • Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
  • Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic 
  • Chemotherapy

  Targeted therapy is the largest segment, as it is more efficient with fewer side effects and focuses on molecular and genetic features differentiating cancer cells.

  Breakup by Cancer Type:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

  Non-Small Cell Lung Cancer (NSCLC) holds the largest market share due to its high prevalence and slower progression compared to SCLC.

  Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

  Hospital pharmacies lead as the primary distribution channel due to the complex and advanced nature of lung cancer therapies requiring controlled administration environments.

  Breakup By Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

  North America dominates the lung cancer therapeutics market, holding the largest regional market share. This is driven by high disease prevalence, advanced healthcare infrastructure, and significant healthcare spending. The region benefits from substantial government and private sector R&D investments, along with favorable regulatory policies for fast-track cancer drugs. High patient awareness and insurance coverage also support the market’s growth in North America.

  Recent Developments & News

  • March 26, 2024: AbbVie Inc. entered into a definitive agreement to acquire clinical-stage biopharmaceutical company Landos Biopharma for $212.5 million, strengthening AbbVie's pipeline in inflammatory and autoimmune therapies.
  • March 19, 2024: AstraZeneca Plc acquired oncology biotech Fusion Pharmaceuticals for $2.4 billion, gaining expertise in targeted and less toxic radiotherapy methods to compete with Novartis.

  Key Players

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • GSK PLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited

  Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=8336&flag=E

  If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

  About Us

  IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

  Contact Us

  IMARC Group,

  134 N 4th St. Brooklyn, NY 11249, USA,

  Email: sales@imarcgroup.com,

  Tel No:+91 120 433 0800,

  United States: +1-201971-6302